Showing results (121-130 of 136) with videos related to
Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|July 12, 2021
Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary TuberculosisAndrew D Gewitz, Belén P Solans, William R Mac Kenzie, et al.The Journal of Cardiovascular Surgery|February 1, 1997
Self-hypnosis reduces anxiety following coronary artery bypass surgery. A prospective, randomized trialC Ashton, G C Whitworth, J A Seldomridge, et al.International Journal of Clinical Practice|March 5, 2014
The impact of brief tobacco treatment training on practice behaviours, self-efficacy and attitudes among healthcare providersT J Payne, N W Gaughf, M J Sutton, et al.Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.Plos One|January 28, 2014
Variability of the QuantiFERON®-TB gold in-tube test using automated and manual methodsWilliam C Whitworth, Donald J Goodwin, Laura Racster, et al.Ebiomedicine|November 5, 2017
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical TrialG B Sigal, M R Segal, A Mathew, et al.Plos One|September 13, 2012
Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube testsWilliam C Whitworth, Lanette R Hamilton, Donald J Goodwin, et al.Journal of Clinical Microbiology|October 14, 2016
Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine ExposureA Jayakumar, R M Savic, C K Everett, et al.Plos One|December 2, 2011
Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigensKathryn L Kellar, Jennifer Gehrke, Stephen E Weis, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.Pageof 14